A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
| Autor: | Prasanna Kumar KM; Bangalore Diabetes Hospital, Bengaluru, Karnataka, India., Ghosh S; Department of Endocrinology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India., Canovatchel W; Janssen Research and Development, LLC, Raritan, NJ, USA., Garodia N; Janssen Medical Affairs, Mumbai, Maharashtra, India., Rajashekar S; Janssen Medical Affairs, Mumbai, Maharashtra, India. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Indian journal of endocrinology and metabolism [Indian J Endocrinol Metab] 2017 Jan-Feb; Vol. 21 (1), pp. 196-209. |
| DOI: | 10.4103/2230-8210.196016 |
| Abstrakt: | Currently available antihyperglycemic agents, despite being effective, provide inadequate glycemic control and/or are associated with side effects or nonadherence. Canagliflozin, a widely used orally active inhibitor of sodium-glucose cotransporter 2 (SGLT2), is a new addition to the therapeutic armamentarium of glucose-lowering drugs. This review summarizes findings from different clinical and observational studies of canagliflozin 300 mg in patients with type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose, thereby increasing urinary glucose excretion in patients with T2DM. Canagliflozin 300 mg has been shown to be effective in lowering glycated hemoglobin, fasting plasma glucose, and postprandial glucose in patients with T2DM. Canagliflozin 300 mg also demonstrated significant reductions in body weight and blood pressure and has a low risk of causing hypoglycemia, when not used in conjunction with insulin and insulin secretagogues. Canagliflozin 300 mg was generally well tolerated in clinical studies. The most frequently reported adverse events include genital mycotic infections, urinary tract infections, osmotic diuresis, and volume depletion-related events. Competing Interests: Dr. K. M. Prasanna Kumar and Dr. Sujoy Ghosh have received honoraria from Johnson and Johnson Pvt. Ltd., India. Dr. William Canovatchel is an employee of Janssen Research and Development, LLC. Dr. Nishant Garodia and Dr. Sujith Rajashekar are employees of Johnson and Johnson Pvt. Ltd, India. We have no other relevant affiliations or financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|